Revolutionizing Bleeding Management - The fibryga® advantage

Acquired fibrinogen deficiency (AFD) is characterized by reduced serum fibrinogen levels, often caused by hemodilution and fibrinogen consumption during significant bleeding events.¹ In critical scenarios such as cardiac surgery, obstetric hemorrhage, and trauma, timely and precise bleeding management is essential in optimizing patient outcomes.^1-3 Historically, fibrinogen repletion relied on cryoprecipitate, which has disadvantages involving variable fibrinogen content, storage requirements, administration delays, and potential pathogen transmission.^1,4 Fibryga^®, the first fibrinogen concentrate approved for AFD, addresses these challenges with precise fibrinogen dosing, simplified storage requirements, extended stability, rapid reconstitution, and improved safety. ^5,6 Fibryga^® dosing may be adjusted depending on plasma fibrinogen levels or viscoelastic testing, severity of bleeding, body weight, or patient’s clinical condition (PI).

This page features recorded lectures from the Octapharma Symposium at the ASA 2024 Annual Meeting, where leading experts shared insights on AFD management in cardiac surgery, postpartum hemorrhage (PPH), and trauma.